Home / Market News / $QNRX
benzinga Corporate Catalyst Impact 65/100 ● neutral

Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

Oct 19, 2026, 12:14 PM UTC · Primary ticker $QNRX

Canaccord Genuity has initiated coverage on Quoin Pharmaceuticals with a 'Buy' rating and an $18 price target. This analyst coverage and positive outlook could generate increased investor interest and potentially boost the stock price.

Canaccord Genuity initiating coverage on Quoin Pharmaceuticals with a 'Buy' rating and an $18 price target is a significant event for the company. Analyst coverage, especially with a positive rating and a specific price target, often brings increased visibility and credibility to a stock. This could attract new investors and lead to short-term upward price movement for QNRX as the market reacts to the new valuation and positive sentiment. In the long term, sustained positive analyst coverage and successful execution by Quoin Pharmaceuticals would be necessary to maintain this momentum. The key opportunity for traders is the potential for a near-term price appreciation following the news.

$QNRX positive Initiated with Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.